Anti-Ebola virus vp40 protein monoclonal antibody f1b4 and its application

Abstract

The invention discloses an anti-Ebola virus VP40 protein monoclonal antibody F1B4 and application thereof. The monoclonal antibody subtype is IgG1, kappa type, can specifically bind with the ZEBOV-VP40 protein C-terminal antigen peptide to exert antiviral effect. A hybridoma cell producing the monoclonal antibody is obtained by fusion of immunized BALB / C mouse spleen lymphocyte and mouse myeloma cell SP2 / 0, screening, cloning and subculture process screening, and can stably secrete F1B4, the heavy chain amino acid sequence of the antibody is SEQ ID No.1, and the light chain amino acid sequenceis shown as SEQ ID No.2. The F1B4 has the antiviral effect of antagonizing Zaire type Ebola virus-like particles, and can be applied in combination with other monoclonal antibodies.

Description

technical field

[0001] The invention belongs to the field of biotechnology, and relates to the preparation and application of anti-Zaire Ebola virus VP40 protein monoclonal antibody, and is a hybridoma cell line that secretes anti-VP40 protein monoclonal antibody by using cell engineering and antibody engineering technology , through the induction of ascites in mice of the same strain, the monoclonal antibody F1B4 against VP40 protein was prepared, identified as IgG1, κ type, the sequence of the antibody was clarified by gene sequencing, and then realized by affinity purification, electrophoresis, immunization, genetic engineering and other technologies Application of the antibody. Background technique

[0002] Ebola virus disease is a fatal hemorrhagic fever caused by Ebola virus infection. In 1976, the Ebola virus was first discovered in southern Sudan and Congo (Kinshasa) (formerly known as Zaire), and then broke out on a small scale in Central Africa. As of 2013, a tota...

Images